The role of surgery in cancer prevention

Current Problems in Surgery

Volumn 47, Issue 10, 2010, Pages 750-830

  Jatoi, Ismail ^a   Benson, John R ^b   Liau, Siong Seng ^b   Chen, Yijun ^c   Cisco, Robin M ^c   Norton, Jeffrey A ^c   Moley, Jeffrey F ^d   Khalifeh, Katherine W ^e   Choti, Michael A ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c STANFORD UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; APOPTOSIS; BREAST NEOPLASMS; CANCER STEM CELL; CHROMOSOMAL INSTABILITY; COLON RESECTION; COLORECTAL NEOPLASMS; FEMALE; GASTRECTOMY; GENE TRANSLOCATION; GENETIC SCREENING; GENETICS; HUMAN; MASTECTOMY; MISMATCH REPAIR; MUTATION; NEOPLASMS; PROCEDURES; QUALITY OF LIFE; RISK FACTOR; STOMACH NEOPLASMS; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR SUPPRESSOR GENE;

ANEUPLOIDY; APOPTOSIS; BREAST NEOPLASMS; CHROMOSOMAL INSTABILITY; COLECTOMY; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; GASTRECTOMY; GENES, TUMOR SUPPRESSOR; GENETIC TESTING; HUMANS; MASTECTOMY; MUTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; QUALITY OF LIFE; RISK FACTORS; STOMACH NEOPLASMS; THYROID NEOPLASMS; THYROIDECTOMY; TRANSLOCATION, GENETIC;

EID: 77956215625     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2010.06.002     Document Type: Article

References (240)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Stewart S.A., Weinberg R.A. Telomeres: cancer to human aging. Annu Rev Cell Dev Biol 2006, 22:531-557.
3. Bodmer W.F. Inherited susceptibility to cancer. Introduction to the Cellular and Molecular Biology of Cancer 1995, Oxford University Press, Oxford. 2nd edition. L.M. Frank, N.M. Teich (Eds.).
4. Knudson A.G. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985, 45:1437-1443.
5. Knudson A.G. Genetics of human cancer. Annu Rev Genet 1986, 20:231-251.
6. Bishop J.M., Weinberg R.A. Molecular oncology 1996, Scientific American Inc, New York.
7. Kinzler K.W., Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997, 386(761):3.
8. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
9. Benson J.R., Baum M., Colletta A.A. Role of TGF beta in the anti-estrogen response/resistance of human breast cancer. J Mammary Gland Biol Neoplasia 1996, 1:381-389.
10. Greaves M. Cancer causation: the Darwinian downside of past success?. Lancet Oncol 2002, 3:244-251.
11. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N Engl J Med 2006, 355:1253-1261.
12. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
13. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
14. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 1973, 243:290-293.
15. Brodeur G.M. Molecular pathology of human neuroblastomas. Semin Diagn Pathol 1994, 11:118-125.
16. Catteau A., Morris J.R. BRCA1 methylation: a significant role in tumour development?. Semin Cancer Biol 2002, 12:359-371.
17. Weaver B.A., Cleveland D.W. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 2007, 67:10103-10105.
18. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
19. Kops G.J., Weaver B.A., Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005, 5:773-785.
20. Lobrich M., Jeggo P.A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 2007, 7:861-869.
21. Mountzios G., Terpos E., Dimopoulos M.A. Aurora kinases as targets for cancer therapy. Cancer Treat Rev 2007, 34:175-182.
22. Hahn W.C. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003, 21:2034-2043.
23. Saldivar J.S., Wu X., Follen M., et al. Nucleotide excision repair pathway review. I: Implications in ovarian cancer and platinum sensitivity. Gynecol Oncol 2007, 107:S56-S71.
24. Leibeling D., Laspe P., Emmert S. Nucleotide excision repair and cancer. J Mol Histol 2006, 37:225-238.
25. Soreide K., Janssen E.A., Soiland H., et al. Microsatellite instability in colorectal cancer. Br J Surg 2006, 93:395-406.
26. Vasen H.F. Review article: the Lynch syndrome (Hereditary nonpolyposis colorectal cancer). Aliment Pharmacol Ther 2007, 26(Suppl 2):113-126.
27. Fishel R., Lescoe M.K., Rao M.R., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75:1027-1038.
28. Butel J.S. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 2000, 21:405-426.
29. Rous P. Viruses and tumour causation. An appraisal of present knowledge. Nature 1965, 207:457-463.
30. Toren A., Ben-Bassat I., Rechavi G. Infectious agents and environmental factors in lymphoid malignancies. Blood Rev 1996, 10:89-94.
31. de Larco J.E., Todaro G.J. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 1978, 75:4001-4005.
32. Turner C.E., Burridge K. Transmembrane molecular assemblies in cell-extracellular matrix interactions. Curr Opin Cell Biol 1991, 3:849-853.
33. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001, 8:161-173.
34. Perona R. Cell signalling: growth factors and tyrosine kinase receptors. Oncol Trans Clin 2006, 8:77-82.
35. Cruz J.J., Ocana A., Del Barco E., et al. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007, 18:421-430.
36. Lo H.W., Hsu S.C., Hung M.C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 2006, 95:211-218.
37. Baselga J., Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001, 12(Suppl 1):S35-S41.
38. Marx S.J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005, 5:367-375.
39. Malumbres M., Barbacid M. Ras oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
40. Mirza A.M., Gysin S., Malek N., et al. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 2004, 24:10868-10881.
41. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
42. Vogel F. Genetics of retinoblastoma. Hum Genet 1979, 52:1-54.
43. Knudson A.G. Cancer genetics. Am J Med Genet 2002, 111:96-102.
44. Harbour J.W., Dean D.C. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2000, 2:E65-E67.
45. Blackburn A.C., Jerry D.J. Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?. Breast Cancer Res 2002, 4:101-111.
46. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
47. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001, 2:731-737.
48. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2:103-112.
49. Ruiz i Altaba A., Sánchez P., Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002, 2:361-372.
50. Hahn H., Wicking C., Zaphiropoulous P.G., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-851.
51. Gorlin R.J. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995, 13:113-125.
52. Benson J.R. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 2004, 5:229-239.
53. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
54. Clevers H. Wnt breakers in colon cancer. Cancer Cell 2004, 5:5-6.
55. Viktorsson K., Lewensohn R., Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005, 94:143-196.
56. Sanchez-Beato M., Sanchez-Aguilera A., Piris M.A. Cell cycle deregulation in B-cell lymphomas. Blood 2003, 101:1220-1235.
57. Cho W.C. Oncomirs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007, 6:60.
58. Garzon R., Croce C.M. microRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008, 15:352-358.
59. Miremadi A., Oestergaard M.Z., Pharoah P.D., et al. Cancer genetics of epigenetic genes. Hum Mol Genet 2007, 16(Spec No. 1):R28-R49.
60. Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 2000, 36:2294-2300.
61. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007, 16(Spec No. 1):R50-R59.
62. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 1999, 18:15-30.
63. Gentile A., Trusolino L., Comoglio P.M. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008, 27:85-94.
64. Pantuck A.J., Zeng G., Belldegrun A.S., et al. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003, 9:4641-4652.
65. Pierce G.B., Speers W.C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988, 48:1996-2004.
66. Schipper H., Goh C.R., Wang T.L. Shifting the cancer paradigm: must we kill to cure?. J Clin Oncol 1995, 13:801-807.
67. Berliner J.L., Fay A.M. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of genetic counselors. J Genet Couns 2007, 16:241-260.
68. Jatoi I., Anderson W.F. Management of women who have a genetic predisposition for breast cancer. Surg Clin North Am 2008, 88:845-861. vii-viii.
69. Zakaria S., Degnim A.C. Prophylactic mastectomy. Surg Clin North Am 2007, 87:317-331. viii.
70. Recht A. Contralateral prophylactic mastectomy: caveat emptor. J Clin Oncol 2009, 27:1347-1349.
71. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62:676-689. The Breast Cancer Linkage Consortium.
72. Robson M., Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007, 357:154-162.
73. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
74. Zon R.T., Goss E., Vogel V.G., et al. American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 2009, 27:986-993.
75. Jatoi I. Breast cancer screening. Am J Surg 1999, 177:518-524.
76. Jatoi I. MRI in breast cancer management: potential for benefit and harm. Int J Fertil Womens Med 2005, 50:281-284.
77. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388.
78. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and raloxifene (star) P-2 trial. JAMA 2006, 295:2727-2741.
79. Cordeiro P.G. Breast reconstruction after surgery for breast cancer. N Engl J Med 2008, 359:1590-1601.
80. Barton M.B., West C.N., Liu I.L., et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr 2005, 35:61-66.
81. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340:77-84.
82. Geiger A.M., Yu O., Herrinton L.J., et al. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. Arch Intern Med 2005, 165:516-520.
83. Meijers-Heijboer H., van Geel B., van Putten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159-164.
84. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93:1633-1637.
85. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the Prose Study Group. J Clin Oncol 2004, 22:1055-1062.
86. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.
87. Yi M., Meric-Bernstam F., Middleton L.P., et al. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 2009, 115:962-971.
88. Hill-Kayser C.E., Harris E.E., Hwang W.T., et al. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. Int J Radiat Oncol Biol Phys 2006, 66:1313-1319.
89. Rosen P.P., Groshen S., Kinne D.W. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991, 9:1650-1661.
90. Pierce L.J., Levin A.M., Rebbeck T.R., et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage. I/II breast cancer. J Clin Oncol 2006, 24:2437-2443.
91. Peralta E.A., Ellenhorn J.D., Wagman L.D., et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000, 180:439-445.
92. McDonnell S.K., Schaid D.J., Myers J.L., et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001, 19:3938-3943.
93. Herrinton L.J., Barlow W.E., Yu O., et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005, 23:4275-4286.
94. Brekelmans C.T., Seynaeve C., Menke-Pluymers M., et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006, 17:391-400.
95. Brekelmans C.T., Tilanus-Linthorst M.M., Seynaeve C., et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007, 43:867-876.
96. Klaren H.M., Van'T Veer L.J., van Leeuwen F.E., et al. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 2003, 95:941-947.
97. Lostumbo L., Carbine N., Wallace J., et al. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004, CD002748.
98. Jatoi I., Anderson W.F. Cancer screening. Curr Probl Surg 2005, 42:620-682.
99. Sjolander A., Humphreys K., Palmgren J. On informative detection bias in screening studies. Stat Med 2008, 27:2635-2650.
100. Jatoi I., Anderson W.F. Breast cancer overdiagnosis with screening mammography. Arch Intern Med 2009, 169:999-1000. [Author reply 1001].
101. Juni P., Egger M. Commentary: empirical evidence of attrition bias in clinical trials. Int J Epidemiol 2005, 34:87-88.
102. Brandberg Y., Sandelin K., Erikson S., et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 2008, 26:3943-3949.
103. Coughlin S.S. Recall bias in epidemiologic studies. J Clin Epidemiol 1990, 43:87-91.
104. Tuttle T.M., Habermann E.B., Grund E.H., et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 2007, 25:5203-5209.
105. Tuttle T.M., Jarosek S., Habermann E.B., et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009, 27:1362-1367.
106. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:2328-2335.
107. Katipamula R., Degnim A.C., Hoskin T., et al. Trends in mastectomy rates at the Mayo Clinic, Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009, 27:4082-4088.
108. Alberts S.R., Cervantes A., van de Velde C.J. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003, 14(Suppl 2):ii31-ii36.
109. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
110. Ekstrom A.M., Serafini M., Nyren O., et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer 2000, 87:133-140.
111. Pharoah P.D., Guilford P., Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001, 121:1348-1353.
112. Caldas C., Carneiro F., Lynch H.T., et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999, 36:873-880.
113. Keller G., Vogelsang H., Becker I., et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999, 155:337-342.
114. Brooks-Wilson A.R., Kaurah P., Suriano G., et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004, 41:508-517.
115. Norton J.A., Ham C.M., Van Dam J., et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007, 245:873-879.
116. Hebbard P.C., Macmillan A., Huntsman D., et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol 2009, 16:1890-1895.
117. Suriano G., Yew S., Ferreira P., et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 2005, 11:5401-5409.
118. Huntsman D.G., Carneiro F., Lewis F.R., et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001, 344:1904-1909.
119. Chun Y.S., Lindor N.M., Smyrk T.C., et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?. Cancer 2001, 92:181-187.
120. Lewis F.R., Mellinger J.D., Hayashi A., et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery 2001, 130:612-617. Discussion 617-9.
121. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
122. Humar B., Guilford P. Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer Sci 2009, 100:1151-1157.
123. Blair V., Martin I., Shaw D., et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006, 4:262-275.
124. Suriano G., Seixas S., Rocha J., et al. A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med 2006, 84:1023-1031.
125. Berx G., Cleton-Jansen A.M., Nollet F., et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995, 14:6107-6115.
126. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991, 251:1451-1455.
127. Cisco R.M., Ford J.M., Norton J.A. Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer 2008, 113:1850-1856.
128. Rogers W.M., Dobo E., Norton J.A., et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008, 32:799-809.
129. Barber M., Murrell A., Ito Y., et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 2008, 216:295-306.
130. Grady W.M., Willis J., Guilford P.J., et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000, 26:16-17.
131. Oliveira C., de Bruin J., Nabais S., et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene 2004, 23:2236-2240.
132. Oliveira C., Sousa S., Pinheiro H., et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009, 136:2137-2148.
133. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996, 14:1730-1736. Discussion 1737-40.
134. Cisco R.M., Norton J.A. Hereditary diffuse gastric cancer: surgery, surveillance and unanswered questions. Future Oncol 2008, 4:553-559.
135. Oliveira C., Bordin M.C., Grehan N., et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002, 19:510-517.
136. Shaw D., Blair V., Framp A., et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy?. Gut 2005, 54:461-468.
137. Barber M.E., Save V., Carneiro F., et al. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 2008, 216:286-294.
138. Charlton A., Blair V., Shaw D., et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004, 53:814-820.
139. Fitzgerald R.C., Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut 2004, 53:775-778.
140. Maehara Y., Baba H., Oda S., et al. [Diagnosis and treatment for familial gastric cancer]. Gan To Kagaku Ryoho 2002, 29:523-531.
141. Caron O., Schielke A., Svrcek M., et al. Usefulness of prophylactic gastrectomy in a novel large hereditary diffuse gastric cancer (HDGC) family. Am J Gastroenterol 2008, 103:2160-2161.
142. Miwa K., Kinami S., Sato T., et al. [Vagus-saving D2 procedure for early gastric carcinoma]. Nippon Geka Gakkai Zasshi 1996, 97:286-290.
143. Ando S., Tsuji H. Surgical technique of vagus nerve-preserving gastrectomy with D2 lymphadenectomy for gastric cancer. Aust NZ J Surg 2008, 78:172-176.
144. Kojima K., Yamada H., Inokuchi M., et al. Functional evaluation after vagus-nerve-sparing laparoscopically assisted distal gastrectomy. Surg Endosc 2008, 22:2003-2008.
145. Francis W.P., Rodrigues D.M., Perez N.E., et al. Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS 2007, 11:142-147.
146. Dralle H., Gimm O., Simon D., et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998, 22:744-750. Discussion 750-1.
147. Hinze R., Holzhausen H.J., Gimm O., et al. Primary hereditary medullary thyroid carcinoma-C-cell morphology and correlation with preoperative calcitonin levels. Virchows Arch 1998, 433:203-208.
148. Wolfe H.J., Melvin K.E., Cervi-Skinner S.J., et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973, 289:437-441.
149. Moley J.F., DeBenedetti M.K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999, 229:880-887. Discussion 887-8.
150. Howe J.R., Norton J.A., Wells S.A. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A. Results of long-term follow-up. Surgery 1993, 114:1070-1077.
151. Frank-Raue K., Kratt T., Hoppner W., et al. Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene. Eur J Endocrinol 1996, 135:222-225.
152. Quayle F.J., Fialkowski E.A., Benveniste R., et al. Pheochromocytoma penetrance varies by RET mutation in MEN2A. Surgery 2007, 142:800-805. Discussion 805.e1.
153. Kraimps J.L., Denizot A., Carnaille B., et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. World J Surg 1996, 20:808-812. Groupe d'Etude des Tumeurs a calcitonin (GETC, French Calcitonin Tumors Study Group), French association of endocrine surgeons, Discussion 812-3.
154. Bugalho M.J., Limbert E., Sobrinho L.G., et al. A kindred with multiple endocrine neoplasia type 2A associated with pruritic skin lesions. Cancer 1992, 70:2664-2667.
155. Ceccherini I., Romei C., Barone V., et al. Identification of the Cys634 → Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest 1994, 17:201-204.
156. Gagel R.F., Levy M.L., Donovan D.T., et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 1989, 111:802-806.
157. Lemos M.C., Carrilho F., Rodrigues F.J., et al. Early onset of medullary thyroid carcinoma in a kindred with multiple endocrine neoplasia type iia associated with cutaneous lichen amyloidosis. Endocr Pract 2002, 8:19-22.
158. Nunziata V., di Giovanni G., Lettera A.M., et al. Cutaneous lichen amyloidosis associated with multiple endocrine neoplasia type 2A. Henry Ford Hosp Med J 1989, 37:144-146.
159. Seri M., Celli I., Betsos N., et al. A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. Clin Genet 1997, 51:86-90.
160. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996, 276:1575-1579.
161. Moore S.W., Zaahl M.G. Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET. Pediatr Surg Int 2008, 24:521-530.
162. Romeo G., Ceccherini I., Celli J., et al. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 1998, 243:515-520.
163. Yip L., Cote G.J., Shapiro S.E., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003, 138:409-416. Discussion 416.
164. Miller C.A., Ellison E.C. Multiple endocrine neoplasia type. Textbook of Endocrine Surgery 2005, 2B. WB Saunders, Philadelphia. 2nd edition. O.H. Clark, Q.-Y. Duh, E. Kebebew (Eds.).
165. Lips C.J., Landsvater R.M., Hoppener J.W., et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994, 331:828-835.
166. White M.L., Doherty G.M. Multiple endocrine neoplasia. Surg Oncol Clin North Am 2008, 17:439-459. x.
167. Wohllk N., Cote G.J., Bugalho M.M., et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996, 81:3740-3745.
168. Elisei R., Romei C., Cosci B., et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007, 92:4725-4729.
169. Neumann H.P., Bausch B., McWhinney S.R., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002, 346:1459-1466.
170. Fialkowski E.A., DeBenedetti M.K., Moley J.F., et al. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg 2008, 43:188-190.
171. Gagel R.F., Tashjian A.H., Cummings T., et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988, 318:478-484.
172. Niccoli-Sire P., Murat A., Baudin E., et al. Early or prophylactic thyroidectomy in MEN. 2/FMTC gene carriers: results in 71 thyroidectomized patients. Eur J Endocrinol 1999, 141:468-474. The French Calcitonin Tumours Study Group (GETC).
173. Rodriguez G.J., Balsalobre M.D., Pomares F., et al. Prophylactic thyroidectomy in MEN 2 A syndrome: experience in a single center. J Am Coll Surg 2002, 195:159-166.
174. Wells S.A., Skinner M.A. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998, 106:29-34.
175. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
176. Kaufman F.R., Roe T.F., Isaacs H., et al. Metastatic medullary thyroid carcinoma in young children with mucosal neuroma syndrome. Pediatrics 1982, 70:263-267.
177. Samaan N.A., Draznin M.B., Halpin R.E., et al. Multiple endocrine syndrome type IIb in early childhood. Cancer 1991, 68:1832-1834.
178. Hundahl S.A., Cady B., Cunningham M.P., et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000, 89:202-217. U.S. and German Thyroid Cancer Study Group.
179. Sosa J.A., Tuggle C.T., Wang T.S., et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 2008, 93:3058-3065.
180. Machens A., Niccoli-Sire P., Hoegel J., et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003, 349:1517-1525.
181. Skinner M.A., Moley J.A., Dilley W.G., et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005, 353:1105-1113.
182. Guillem J.G., Wood W.C., Moley J.F., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006, 24:4642-4660.
183. Simon S., Pavel M., Hensen J., et al. Multiple endocrine neoplasia 2 A syndrome: surgical management. J Pediatr Surg 2002, 37:897-900.
184. Bae S.J., Kim D.J., Kim J.Y., et al. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A. Thyroidology 2006, 16:609-614.
185. Bethanis S., Koutsodontis G., Palouka T., et al. A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones 2007, 6:152-156.
186. Jimenez C., Dang G.T., Schultz P.N., et al. A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89:3521-3526.
187. Komminoth P., Kunz E.K., Matias-Guiu X., et al. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 1995, 76:479-489.
188. Pigny P., Bauters C., Wemeau J.L., et al. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 1999, 84:1700-1704.
189. Ercolino T., Lombardi A., Becherini L., et al. The Y606C RET mutation causes a receptor gain of function. Clin Endocrinol 2008, 69:253-258.
190. Machens A., Schneyer U., Holzhausen H.J., et al. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. Surgery 2004, 136:1083-1087.
191. Brauckhoff M., Gimm O., Brauckhoff K., et al. Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma. Langenbecks Arch Surg 2001, 386:434-439.
192. Fugazzola L., Pinchera A., Luchetti F., et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994, 9:21-24.
193. Dottorini M.E., Assi A., Sironi M., et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996, 77:1556-1565.
194. Modigliani E., Cohen R., Campos J.M., et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Groupe d'etude des tumeurs a calcitonin. Clin Endocrinol 1998, 48:265-273. The GETC Study Group.
195. Pellegriti G., Leboulleux S., Baudin E., et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 2003, 88:1537-1542.
196. Traugott A., Moley J.F. Medullary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005, 6:339-346.
197. Center M.M., Jemal A., Smith R.A., et al. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009, 59:366-378.
198. Merg A., Lynch H.T., Lynch J.F., et al. Hereditary colon cancer-part I. Curr Probl Surg 2005, 42:195-256.
199. You Y.N., Lakhani V.T., Wells S.A. The role of prophylactic surgery in cancer prevention. World J Surg 2007, 31:450-464.
200. Lippman S.M., Hawk E.T. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 2009, 69:5269-5284.
201. Halbert C.H., Lynch H., Lynch J., et al. Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med 2004, 164:1881-1887.
202. Dove-Edwin I., Sasieni P., Adams J., et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005, 331:1047.
203. Hendriks Y.M., de Jong A.E., Morreau H., et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 2006, 56:213-225.
204. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003, 348:919-932.
205. Merg A., Lynch H.T., Lynch J.F., et al. Hereditary colorectal cancer-part II. Curr Probl Surg 2005, 42:267-333.
206. Lynch H.T., Riley B.D., Weissman S.M., et al. Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer 2004, 100:53-64.
207. Lindor N.M., Rabe K., Petersen G.M., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005, 293:1979-1985.
208. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268.
209. Jarvinen H.J., Mecklin J.P., Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995, 108:1405-1411.
210. Jarvinen H.J., Aarnio M., Mustonen H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118:829-834.
211. Syngal S., Weeks J.C., Schrag D., et al. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998, 129:787-796.
212. Delaney C.P., Fazio V.W., Remzi F.H., et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg 2003, 238:221-228.
213. Rodriguez-Bigas M.A., Vasen H.F., Pekka-Mecklin J., et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. Ann Surg 1997, 225:202-207. International Collaborative Group on HNPCC.
214. Sieber O.M., Lipton L., Crabtree M., et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003, 348:791-799.
215. Al-Sukhni W., Aronson M., Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and Lynch syndrome. Surg Clin North Am 2008, 88:819-844. vii.
216. Lynch P.M. Prevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCC. Digestion 2007, 76:68-76.
217. Bertario L., Presciuttini S., Sala P., et al. Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Semin Surg Oncol 1994, 10:225-234. Italian Registry of Familial Polyposis Writing Committee.
218. Church J., Burke C., McGannon E., et al. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 2003, 46:1175-1181.
219. Lindor N.M., Petersen G.M., Hadley D.W., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006, 296:1507-1517.
220. Schreibman I.R., Baker M., Amos C., et al. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol 2005, 100:476-490.
221. Calva D., Howe J.R. Hamartomatous polyposis syndromes. Surg Clin North Am 2008, 88:779-817. vii.
222. Lakatos P.L., Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008, 14:3937-3947.
223. Shih D.Q., Targan S.R. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008, 14:390-400.
224. Xie J., Itzkowitz S.H. Cancer in inflammatory bowel disease. World J Gastroenterol 2008, 14:378-389.
225. Oseni T., Jatoi I. An overview of the role of prophylactic surgery in the management of individuals with a hereditary cancer predisposition. Surg Clin North Am 2008, 88:739-758. vi.
226. Brown C.J., Maclean A.R., Cohen Z., et al. Crohn's disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure. Dis Colon Rectum 2005, 48:1542-1549.
227. Remzi F.H., Church J.M., Bast J., et al. Mucosectomy vs stapled ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: functional outcome and neoplasia control. Dis Colon Rectum 2001, 44:1590-1596.
228. Bulow C., Vasen H., Jarvinen H., et al. Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 2000, 119:1454-1460.
229. Kartheuser A., Stangherlin P., Brandt D., et al. Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited. Fam Cancer 2006, 5:241-260. Discussion 261-2.
230. Nieuwenhuis M.H., Bulow S., Bjork J., et al. Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. Dis Colon Rectum 2009, 52:1259-1263.
231. van Duijvendijk P., Vasen H.F., Bertario L., et al. Cumulative risk of developing polyps or malignancy at the ileal pouch-anal anastomosis in patients with familial adenomatous polyposis. J Gastrointest Surg 1999, 3:325-330.
232. de Vos tot Nederveen Cappel W.H., Buskens E., van Duijvendijk P., et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 2003, 52:1752-1755.
233. You Y.N., Chua H.K., Nelson H., et al. Segmental vs extended colectomy: measurable differences in morbidity, function, and quality of life. Dis Colon Rectum 2008, 51:1036-1043.
234. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004, 350:2050-2059. Clinical Outcomes of Surgical Therapy Study Group.
235. Kuhry E., Schwenk W.F., Gaupset R., et al. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008, CD003432.
236. Ahmed A.U., Keus F., Heikens J.T., et al. Open vs laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev 2009, CD006267.
237. Lefevre J.H., Parc Y., Kerneis S., et al. Risk factors for development of desmoid tumours in familial adenomatous polyposis. Br J Surg 2008, 95:1136-1139.
238. Kelly J., Condon E.T., Redmond H.P., et al. The benefits of a laparoscopic approach in ileal pouch anal anastomosis formation: a single institutional retrospective case-matched experience. Ir J Med Sci 2009, 179:197-200.
239. Zhang H., Hu S., Zhang G., et al. Laparoscopic vs open proctocolectomy with ileal pouch-anal anastomosis. Minim Invasive Ther Allied Technol 2007, 16:187-191.
240. Fichera A., Silvestri M.T., Hurst R.D., et al. Laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis: a comparative observational study on long-term functional results. J Gastrointest Surg 2009, 13:526-532.